Introduction: Acute promyelocytic leukemia (APL) is genetically characterized by the fusion of promyelocytic leukemia (PML) gene with retinoic acid receptor alpha (RARα) resulting from a t(15;17)(q24;q21) chromosomal translocation. An infrequent but recurrent finding in APL is the formation of an isochromosome of the derivative chromosome 17; ider(17)(q10)t(15;17) or ider(17q). This rearrangement in APL results in an additional copy of the PML-RARα fusion gene as well as loss of 17p/TP53. Due to the infrequent occurrence of the ider(17q), the prognostic impact of this genetic finding is not well known. Case Presentation(s): Here, we describe the clinical characteristics and outcomes of our case series of 5 patients with ider(17q) APL treated at the University of Maryland and Johns Hopkins University. Conclusion: In our series, patients with APL with ider(17q) did not have a worse prognosis.

1.
Hillestad
LK
.
Acute promyelocytc leukemia
.
Acta Med Scand
.
1957
;
159
(
3
):
189
94
.
2.
Lavau
C
,
Dejean
A
.
The t(15;17) translocation in acute promyelocytic leukemia
.
Leukemia
.
1994
;
8
(
10
):
1615
21
.
3.
Lo-Coco
F
,
Avvisati
G
,
Vignetti
M
,
Thiede
C
,
Orlando
SM
,
Iacobelli
S
, et al
.
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
.
N Engl J Med
.
2013
;
369
(
2
):
111
21
.
4.
Burnett
AK
,
Russell
NH
,
Hills
RK
,
Bowen
D
,
Kell
J
,
Knapper
S
, et al
.
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
.
Lancet Oncol
.
2015
;
16
(
13
):
1295
305
.
5.
Cicconi
L
,
Platzbecker
U
,
Avvisati
G
,
Paoloni
F
,
Thiede
C
,
Vignetti
M
, et al
.
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial
.
Leukemia
.
2020
;
34
(
3
):
914
8
.
6.
Li
AY
,
Kashanian
SM
,
Hambley
BC
,
Zacholski
K
,
Duong
VH
,
El Chaer
F
, et al
.
FLT3-ITD allelic burden and acute promyelocytic leukemia risk stratification
.
Biology
.
2021
;
10
(
3
):
243
.
7.
Manola
KN
,
Karakosta
M
,
Sambani
C
,
Terzoudi
G
,
Pagoni
M
,
Gatsa
E
, et al
.
Isochromosome der(17)(q10)t(15;17) in acute promyelocytic leukemia resulting in an additional copy of the RARA-PML fusion gene: report of 4 cases and review of the literature
.
Acta Haematol
.
2010
;
123
(
3
):
162
70
.
8.
Koczkodaj
D
,
Muzyka-Kasietczuk
J
,
Chocholska
S
,
Podhorecka
M
.
Prognostic significance of isochromosome 17q in hematologic malignancies
.
Oncotarget
.
2021
;
12
(
7
):
708
18
.
9.
Papaemmanuil
E
,
Gerstung
M
,
Bullinger
L
,
Gaidzik
VI
,
Paschka
P
,
Roberts
ND
, et al
.
Genomic classification and prognosis in acute myeloid leukemia
.
N Engl J Med
.
2016
;
374
(
23
):
2209
21
.
10.
Seifert
H
,
Mohr
B
,
Thiede
C
,
Oelschlägel
U
,
Schäkel
U
,
Illmer
T
, et al
.
The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia
.
Leukemia
.
2009
;
23
(
4
):
656
63
.
11.
Barbouti
A
,
Stankiewicz
P
,
Nusbaum
C
,
Cuomo
C
,
Cook
A
,
Höglund
M
, et al
.
The breakpoint region of the most common isochromosome, i(17q), in human neoplasia is characterized by a complex genomic architecture with large, palindromic, low-copy repeats
.
Am J Hum Genet
.
2004
;
74
(
1
):
1
10
.
12.
Sanz
MA
,
Montesinos
P
,
Vellenga
E
,
Rayón
C
,
de la Serna
J
,
Parody
R
, et al
.
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
.
Blood
.
2008
;
112
(
8
):
3130
4
.
13.
Fenaux
P
,
Chastang
C
,
Chevret
S
,
Sanz
M
,
Dombret
H
,
Archimbaud
E
, et al
.
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
.
Blood
.
1999
;
94
(
4
):
1192
200
.
14.
Shen
ZX
,
Chen
GQ
,
Ni
JH
,
Li
XS
,
Xiong
SM
,
Qiu
QY
, et al
.
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
.
Blood
.
1997
;
89
(
9
):
3354
60
.
15.
Campo
E
,
Cymbalista
F
,
Ghia
P
,
Jäger
U
,
Pospisilova
S
,
Rosenquist
R
, et al
.
TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
.
Haematologica
.
2018
;
103
(
12
):
1956
68
.
16.
Middeke
JM
,
Fang
M
,
Cornelissen
JJ
,
Mohr
B
,
Appelbaum
FR
,
Stadler
M
, et al
.
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
.
Blood
.
2014
;
123
(
19
):
2960
7
.
17.
Gu
W
,
Roeder
RG
.
Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
.
Cell
.
1997
;
90
(
4
):
595
606
.
18.
Chen
GQ
,
Shi
XG
,
Tang
W
,
Xiong
SM
,
Zhu
J
,
Cai
X
, et al
.
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells
.
Blood
.
1997
;
89
(
9
):
3345
53
.
19.
Wang
H
,
Wang
X
,
Xu
L
,
Zhang
J
.
TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
.
FEBS Open Bio
.
2022
;
12
(
3
):
616
26
.
20.
Liu
Q
,
Hilsenbeck
S
,
Gazitt
Y
.
Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL
.
Blood
.
2003
;
101
(
10
):
4078
87
.
21.
Bernard
E
,
Nannya
Y
,
Hasserjian
RP
,
Devlin
SM
,
Tuechler
H
,
Medina-Martinez
JS
, et al
.
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
.
Nat Med
.
2020
;
26
(
10
):
1549
56
.
22.
Malcikova
J
,
Smardova
J
,
Rocnova
L
,
Tichy
B
,
Kuglik
P
,
Vranova
V
, et al
.
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage
.
Blood
.
2009
;
114
(
26
):
5307
14
.
23.
Xue
Y
,
Lu
D
,
Guo
Y
,
Lin
B
.
Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis
.
Leuk Res
.
1992
;
16
(
11
):
1113
23
.
24.
Park
JP
,
Fairweather
RB
,
Mohandas
TK
.
Isochromosome for derivative 17q in acute promyelocytic leukemia: evidence for two copies of PML-RARA and favorable response to all-trans-retinoic acid therapy
.
Genes Chromosomes Cancer
.
1997
;
18
(
2
):
151
3
.
25.
Chou
WC
,
Tang
JL
,
Yao
M
,
Liang
YJ
,
Lee
FY
,
Lin
MT
, et al
.
Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment
.
Leukemia
.
1997
;
11
(
7
):
921
8
.
26.
Okoshi
Y
,
Akiyama
H
,
Kono
N
,
Matsumura
T
,
Mizuchi
D
,
Mori
S
, et al
.
Effect of additional chromosomal abnormalities in acute promyelocytic leukemia treated with all-trans-retinoic acid: a report of 17 patients
.
Int J Hematol
.
2001
;
73
(
4
):
496
501
.
27.
Kim
M
,
Lee
SA
,
Park
H
,
Oh
EJ
,
Park
CW
,
Lim
J
, et al
.
Two distinct clonal populations in acute promyelocytic leukemia, one involving chromosome 17 and the other involving an isochromosome 17
.
Cancer Genet Cytogenet
.
2010
;
197
(
2
):
185
8
.
28.
Schoch
C
,
Haase
D
,
Haferlach
T
,
Freund
M
,
Link
H
,
Lengfelder
E
, et al
.
Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients
.
Br J Haematol
.
1996
;
94
(
3
):
493
500
.
29.
Hiorns
LR
,
Swansbury
GJ
,
Mehta
J
,
Min
T
,
Dainton
MG
,
Treleaven
J
, et al
.
Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia
.
Br J Haematol
.
1997
;
96
(
2
):
314
21
.
30.
Xu
L
,
Zhao
WL
,
Xiong
SM
,
Su
XY
,
Zhao
M
,
Wang
C
, et al
.
Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia
.
Leukemia
.
2001
;
15
(
9
):
1359
68
.
31.
Lee
GY
,
Christina
S
,
Tien
SL
,
Ghafar
ABA
,
Hwang
W
,
Lim
LC
, et al
.
Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia
.
Cancer Genet Cytogenet
.
2005
;
159
(
2
):
129
36
.
32.
Inamura
J
,
Ikuta
K
,
Tsukada
N
,
Hosoki
T
,
Shindo
M
,
Sato
K
.
Acute promyelocytic leukemia with i(17)(q10)
.
Intern Med
.
2016
;
55
(
22
):
3341
5
.
33.
Grimwade
D
,
Howe
K
,
Langrbeer
S
,
Davis
L
,
Oliver
F
,
Walker
H
, et al
.
Establishing the presence of the t( 15; 17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial
.
Br J Haematol
.
1996
;
94
(
3
):
557
73
.
34.
Tong
H
,
Li
K
,
Mei
C
,
Wang
H
,
Chen
Z
,
Jin
J
.
Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid
.
Ann Hematol
.
2011
;
90
(
12
):
1493
4
.
35.
Tang
Y
,
Wang
Y
,
Hu
L
,
Meng
F
,
Xu
D
,
Wan
K
, et al
.
Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature
.
Int J Clin Exp Pathol
.
2015
;
8
(
11
):
15294
300
.
36.
Shepshelovich
D
,
Oniashvili
N
,
Parnes
D
,
Klein
A
,
Muchtar
E
,
Yeshaya
J
, et al
.
Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide
.
Cancer Genet
.
2015
;
208
(
11
):
575
9
.
You do not currently have access to this content.